The company's patented and patent-pending technology allows for the creation of devices that can be designed and fabricated for specific tumor types, with their first product, the CivaString, having been granted FDA 510k clearance to treat any solid tumor. By substantially reducing procedure time and providing homogeneous dose distribution, Civatech Oncology's devices minimize trauma and enable radiation oncologists to deliver individualized, targeted therapy for the treatment of early-stage cancers.